MicroPort<sup>®</sup> Attends TCT 2015

Shanghai MicroPort Medical (Group) Co ("MicroPort") attended the 27th Transcatheter Cardiovascular Therapeutics (TCT) in San Francisco from October 11 to October 15, to further promote its third-generation Drug Eluting Stent ("DES") Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk®"). As the world's largest and most influential interventional cardiology conference, TCT attracted more than 13,000 industry professionals to participate this year.
 
In the session themed with "Metallic Drug-Eluting Stents: Tomorrow's Technology" on Oct 12, Professor Bo Xu from Fuwai Hospital, announced the long-term follow-up clinical study results of Firehawk® TARGET series, including the latest five-year clinical findings of TARGET FIM, the latest four-year clinical findings of TARGET I RCT and TARGET I long. The results of the three studies showed that the thrombosis incidence of Firehawk® was all 0%. The recurrence rate of myocardial infarction was 4.8%, 1.4% and 4.3% in these studies respectively. The target lesion revascularization rate driven by ischemia was 0%, 2.3% and 6.4%. The TARGET series clinical outcomes strongly proved the safety and efficacy of Firehawk® in the long-term clinical application.
 
During the meeting, Professor Xu further announced the design scheme of TARGET All Comer, Firehawk®'s post-market clinical trial in Europe. The trial is expected to be carried out in 20 sites across 10 European countries involving a total of 1656 patients. At present, the preparation of Firehawk® TARGET ALL Comer clinical trial has been completed, and the enrollment of the first patient will be carried out in Europe soon.
 
The 2nd Executive Committee Meeting of Firehawk® TARGET ALL Comer was held on October 13. The executive committee members include Professor William Wijns, President of EuroPCR and Primary Investigator of the trial, Professor Alexandra Lansky and Professor Andreas Baumbach, two Co-Primary Investigators respectively from Yale Cardiology and Bristol Heart Center and Professor Xu. The meeting focused on the trial progress, the final selection of sites, the treatment program of dual antiplatelet therapy and the latest European guidelines.
 
Amid the complex case sharing on Oct 14, Dr. Ferdinand Kiemeneij, the first physician using Firehawk® in Europe, shared his clinical experience of applying Firehawk® in treating complex lesions. The case was a CTO one with three Firehawk® stents implanted by using Chameleon technique. Dr. Kiemeneij was satisfied with the case results and also recognized Firehawk®'s excellent performance in treating complex lesions.